46.2% of subjects receiving iPPS showed a greater than 50% reduction in pain from baseline
compared to 22.5% of subjects receiving Placebo under KOOS pain subscale in the NRS Pain
= 4-6 strata. This is highly statistically significant at p=0.026 and highly clinically meaningful
i.e. subjects received a pain reduction of 50% or more
Ann: PAR Reports Successful Phase 2 Clinical Trial, page-2
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.5¢ | 23.0¢ | $74.06K | 320.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 102830 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 703 | 1 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |